retatrutide news october 2025 Medscape | Retatrutide, an investigational triple hormone receptor agonist that shows promise for weight loss in ongoing phase-3 clinical trials, is Retatrutide Promises Big Weight Loss,

Drug therapy replaced the use of KD over the following decades ( 3 Ketogenic diet The World Health Organization (WHO) recommends that adults limit their total fat intake to less than 30% of their daily energy intake ( KD significantly deviates from standard healthy nutrition recommendations

Odutayo A, Wong CX, Hsiao AJ, Hopewell S, Altman DG, Emdin CA

This "step therapy" approach, common in pharmaceutical benefit management, could make orforglipron the default first-line GLP-1 therapy for many patients, with injectable options reserved for orforglipron non-responders or patients with specific clinical needs for higher efficacy

For its systemic effects, DSIP is very similar to melatonin in that regard

10.5601/jelem.2013.18.1.13 262